retatrutide nonalcoholic steatohepatitis trial NASH Study | Fatty Liver Disease Clinical Retatrutide for weight loss: Study

Shibuya T, Fushimi N, Kawai M et al (2018) Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study

Restrictions apply

GLP-1 RAs are first-choice medications [archived link] to help adults achieve (and maintain) weight loss

Antiobesity medications have specific mode of action such as reducing dietary intake, modifying energy metabolism, and increasing energy expenditure or both [8,9]

J., Gratzl, S., Goodwin Cartwright, B

12,13 By virtue of having both diabetes and CKD, this population is considered to be at high risk for CVD